HEADER HYDROLASE/HYDROLASE INHIBITOR 20-JAN-94 1PPK TITLE CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO TITLE 2 PENICILLOPEPSIN: PHOSPHOROUS-CONTAINING PEPTIDE ANALOGUES COMPND MOL_ID: 1; COMPND 2 MOLECULE: PENICILLOPEPSIN; COMPND 3 CHAIN: E; COMPND 4 EC: 3.4.23.20; COMPND 5 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: PENICILLIUM JANTHINELLUM; SOURCE 3 ORGANISM_TAXID: 5079 KEYWDS ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR N.C.J.STRYNADKA,M.N.G.JAMES REVDAT 6 29-JUL-20 1PPK 1 COMPND REMARK HETNAM LINK REVDAT 6 2 1 SITE ATOM REVDAT 5 13-JUL-11 1PPK 1 VERSN REVDAT 4 25-AUG-09 1PPK 1 SOURCE REVDAT 3 24-FEB-09 1PPK 1 VERSN REVDAT 2 01-APR-03 1PPK 1 JRNL REVDAT 1 31-MAY-94 1PPK 0 JRNL AUTH M.E.FRASER,N.C.STRYNADKA,P.A.BARTLETT,J.E.HANSON,M.N.JAMES JRNL TITL CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION-STATE MIMICS BOUND JRNL TITL 2 TO PENICILLOPEPSIN: PHOSPHORUS-CONTAINING PEPTIDE ANALOGUES. JRNL REF BIOCHEMISTRY V. 31 5201 1992 JRNL REFN ISSN 0006-2960 JRNL PMID 1606144 JRNL DOI 10.1021/BI00137A016 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH M.N.G.JAMES,A.R.SIELECKI,K.HAYAKAWA,M.H.GELB REMARK 1 TITL CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND REMARK 1 TITL 2 TO PENICILLOPEPSIN: DIFLUOROSTATINE-AND REMARK 1 TITL 3 DIFLUOROSTATONE-CONTAINING PEPTIDES REMARK 1 REF BIOCHEMISTRY V. 31 3872 1992 REMARK 1 REFN ISSN 0006-2960 REMARK 1 REFERENCE 2 REMARK 1 AUTH M.N.G.JAMES,A.R.SIELECKI REMARK 1 TITL ASPARTIC PROTEINASES AND THEIR CATALYTIC PATHWAY REMARK 1 EDIT F.A.JURNAK, A.MCPHERSON REMARK 1 REF BIOLOGICAL MACROMOLECULES V. 3 414 1987 REMARK 1 REF 2 AND ASSEMBLIES REMARK 1 PUBL JOHN WILEY AND SONS,NEW YORK REMARK 1 REFN ISSN 0-471-85142-6 REMARK 1 REFERENCE 3 REMARK 1 AUTH M.N.G.JAMES,A.R.SIELECKI REMARK 1 TITL STEREOCHEMICAL ANALYSIS OF PEPTIDE BOND HYDROLYSIS CATALYZED REMARK 1 TITL 2 BY THE ASPARTIC PROTEINASE PENICILLOPEPSIN REMARK 1 REF BIOCHEMISTRY V. 24 3701 1985 REMARK 1 REFN ISSN 0006-2960 REMARK 1 REFERENCE 4 REMARK 1 AUTH M.N.G.JAMES,A.R.SIELECKI,T.HOFMANN REMARK 1 TITL X-RAY DIFFRACTION STUDIES ON PENICILLOPEPSIN AND ITS REMARK 1 TITL 2 COMPLEXES: THE HYDROLYTIC MECHANISM REMARK 1 EDIT V.KOSTKA REMARK 1 REF ASPARTIC PROTEINASES AND 163 1985 REMARK 1 REF 2 THEIR INHIBITORS REMARK 1 PUBL WALTER DE GRUYTER & CO.,BERLIN REMARK 1 REFN REMARK 1 REFERENCE 5 REMARK 1 AUTH T.HOFMANN,R.S.HODGES,M.N.G.JAMES REMARK 1 TITL EFFECT OF PH ON THE ACTIVITIES OF PENICILLOPEPSIN AND REMARK 1 TITL 2 RHIZOPUS PEPSIN AND A PROPOSAL FOR THE PRODUCTIVE SUBSTRATE REMARK 1 TITL 3 BINDING MODE IN PENICILLOPEPSIN REMARK 1 REF BIOCHEMISTRY V. 23 635 1984 REMARK 1 REFN ISSN 0006-2960 REMARK 1 REFERENCE 6 REMARK 1 AUTH M.N.G.JAMES,A.R.SIELECKI,J.MOULT REMARK 1 TITL CRYSTALLOGRAPHIC ANALYSIS OF A PEPSTATIN ANALOGUE BINDING TO REMARK 1 TITL 2 THE ASPARTYL PROTEINASE PENICILLOPEPSIN AT 1.8 ANGSTROMS REMARK 1 TITL 3 RESOLUTION REMARK 1 EDIT V.J.HRUBY, D.H.RICH REMARK 1 REF PEPTIDES: STRUCTURE AND 521 1983 REMARK 1 REF 2 FUNCTION, PROCEEDINGS OF THE REMARK 1 REF 3 OF THE EIGHTH AMERICAN REMARK 1 REF 4 PEPTIDE SYMPOSIUM REMARK 1 PUBL PIERCE CHEMICAL COMPANY,ROCKFORD,IL REMARK 1 REFN REMARK 1 REFERENCE 7 REMARK 1 AUTH M.N.G.JAMES,A.R.SIELECKI REMARK 1 TITL STRUCTURE AND REFINEMENT OF PENICILLOPEPSIN AT 1.8 ANGSTROMS REMARK 1 TITL 2 RESOLUTION REMARK 1 REF J.MOL.BIOL. V. 163 299 1983 REMARK 1 REFN ISSN 0022-2836 REMARK 1 REFERENCE 8 REMARK 1 AUTH M.N.G.JAMES,A.SIELECKI,F.SALITURO,D.H.RICH,T.HOFMANN REMARK 1 TITL CONFORMATIONAL FLEXIBILITY IN THE ACTIVE SITES OF ASPARTYL REMARK 1 TITL 2 PROTEINASES REVEALED BY A PEPSTATIN FRAGMENT BINDING TO REMARK 1 TITL 3 PENICILLOPEPSIN REMARK 1 REF PROC.NATL.ACAD.SCI.USA V. 79 6137 1982 REMARK 1 REFN ISSN 0027-8424 REMARK 2 REMARK 2 RESOLUTION. 1.80 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PROLSQ REMARK 3 AUTHORS : KONNERT,HENDRICKSON REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.80 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 8.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 3.000 REMARK 3 COMPLETENESS FOR RANGE (%) : NULL REMARK 3 NUMBER OF REFLECTIONS : 22145 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : NULL REMARK 3 R VALUE (WORKING + TEST SET) : 0.132 REMARK 3 R VALUE (WORKING SET) : NULL REMARK 3 FREE R VALUE : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : NULL REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : NULL REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : NULL REMARK 3 FREE R VALUE (NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2366 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 65 REMARK 3 SOLVENT ATOMS : 275 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 DISTANCE RESTRAINTS. RMS SIGMA REMARK 3 BOND LENGTH (A) : 0.022 ; 0.018 REMARK 3 ANGLE DISTANCE (A) : 0.044 ; 0.032 REMARK 3 INTRAPLANAR 1-4 DISTANCE (A) : 0.046 ; 0.032 REMARK 3 H-BOND OR METAL COORDINATION (A) : NULL ; NULL REMARK 3 REMARK 3 PLANE RESTRAINT (A) : 0.018 ; 0.018 REMARK 3 CHIRAL-CENTER RESTRAINT (A**3) : 0.213 ; 0.180 REMARK 3 REMARK 3 NON-BONDED CONTACT RESTRAINTS. REMARK 3 SINGLE TORSION (A) : 0.250 ; 0.360 REMARK 3 MULTIPLE TORSION (A) : 0.182 ; 0.360 REMARK 3 H-BOND (X...Y) (A) : NULL ; NULL REMARK 3 H-BOND (X-H...Y) (A) : 0.204 ; 0.360 REMARK 3 REMARK 3 CONFORMATIONAL TORSION ANGLE RESTRAINTS. REMARK 3 SPECIFIED (DEGREES) : NULL ; NULL REMARK 3 PLANAR (DEGREES) : NULL ; NULL REMARK 3 STAGGERED (DEGREES) : NULL ; NULL REMARK 3 TRANSVERSE (DEGREES) : NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.900 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.800 ; 2.500 REMARK 3 SIDE-CHAIN BOND (A**2) : 3.400 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 5.000 ; 3.200 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1PPK COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY BNL. REMARK 100 THE DEPOSITION ID IS D_1000175789. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : NULL REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : NULL REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : NULL REMARK 200 RADIATION SOURCE : NULL REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : NULL REMARK 200 WAVELENGTH OR RANGE (A) : NULL REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : NULL REMARK 200 DETECTOR MANUFACTURER : NULL REMARK 200 INTENSITY-INTEGRATION SOFTWARE : NULL REMARK 200 DATA SCALING SOFTWARE : NULL REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : NULL REMARK 200 RESOLUTION RANGE HIGH (A) : 1.800 REMARK 200 RESOLUTION RANGE LOW (A) : NULL REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : NULL REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: NULL REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: NULL REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 38.20 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.99 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 48.74000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 23.27500 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 48.74000 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 23.27500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: E REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 HOH E 614 LIES ON A SPECIAL POSITION. REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 SER E 36 CB SER E 36 OG 0.093 REMARK 500 GLY E 205 N GLY E 205 CA 0.096 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 THR E 9 CA - CB - CG2 ANGL. DEV. = -11.9 DEGREES REMARK 500 ASP E 33 CB - CG - OD2 ANGL. DEV. = 7.2 DEGREES REMARK 500 SER E 52 O - C - N ANGL. DEV. = 10.7 DEGREES REMARK 500 ASN E 118 O - C - N ANGL. DEV. = 10.0 DEGREES REMARK 500 PRO E 134 N - CD - CG ANGL. DEV. = -8.0 DEGREES REMARK 500 PHE E 141 CB - CG - CD1 ANGL. DEV. = -4.2 DEGREES REMARK 500 ASP E 142 CB - CG - OD1 ANGL. DEV. = 13.1 DEGREES REMARK 500 TYR E 165 CB - CG - CD2 ANGL. DEV. = -4.4 DEGREES REMARK 500 ASP E 196 OD1 - CG - OD2 ANGL. DEV. = 12.8 DEGREES REMARK 500 ASP E 196 CB - CG - OD1 ANGL. DEV. = -7.4 DEGREES REMARK 500 ASP E 206 OD1 - CG - OD2 ANGL. DEV. = -12.9 DEGREES REMARK 500 ASP E 206 CB - CG - OD1 ANGL. DEV. = 13.4 DEGREES REMARK 500 ASP E 222 CB - CG - OD1 ANGL. DEV. = 6.5 DEGREES REMARK 500 ASP E 222 CB - CG - OD2 ANGL. DEV. = -9.2 DEGREES REMARK 500 TYR E 230 CB - CG - CD1 ANGL. DEV. = -3.8 DEGREES REMARK 500 GLN E 237 CB - CG - CD ANGL. DEV. = 19.7 DEGREES REMARK 500 LEU E 317 O - C - N ANGL. DEV. = 10.5 DEGREES REMARK 500 PHE E 319 CB - CG - CD2 ANGL. DEV. = -4.5 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR E 62 -8.51 -142.01 REMARK 500 ASP E 279 84.22 -157.18 REMARK 500 REMARK 500 REMARK: NULL REMARK 630 REMARK 630 MOLECULE TYPE: PEPTIDE-LIKE INHIBITOR REMARK 630 MOLECULE NAME: N-(3-METHYLBUTANOYL)-L-VALYL-N-{(1R)-1-[(R)-(2- REMARK 630 ETHOXY-2-OXOETHYL)(HYDROXY)PHOSPHORYL]-3-METHYLBUTYL}-L-VALINAMIDE REMARK 630 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 630 SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 630 REMARK 630 M RES C SSSEQI REMARK 630 IVV E 700 REMARK 630 SOURCE: NULL REMARK 630 TAXONOMY: NULL REMARK 630 SUBCOMP: IVA VAL VAL PT0 REMARK 630 DETAILS: NULL DBREF 1PPK E 1 323 UNP P00798 PENP_PENJA 1 323 SEQRES 1 E 323 ALA ALA SER GLY VAL ALA THR ASN THR PRO THR ALA ASN SEQRES 2 E 323 ASP GLU GLU TYR ILE THR PRO VAL THR ILE GLY GLY THR SEQRES 3 E 323 THR LEU ASN LEU ASN PHE ASP THR GLY SER ALA ASP LEU SEQRES 4 E 323 TRP VAL PHE SER THR GLU LEU PRO ALA SER GLN GLN SER SEQRES 5 E 323 GLY HIS SER VAL TYR ASN PRO SER ALA THR GLY LYS GLU SEQRES 6 E 323 LEU SER GLY TYR THR TRP SER ILE SER TYR GLY ASP GLY SEQRES 7 E 323 SER SER ALA SER GLY ASN VAL PHE THR ASP SER VAL THR SEQRES 8 E 323 VAL GLY GLY VAL THR ALA HIS GLY GLN ALA VAL GLN ALA SEQRES 9 E 323 ALA GLN GLN ILE SER ALA GLN PHE GLN GLN ASP THR ASN SEQRES 10 E 323 ASN ASP GLY LEU LEU GLY LEU ALA PHE SER SER ILE ASN SEQRES 11 E 323 THR VAL GLN PRO GLN SER GLN THR THR PHE PHE ASP THR SEQRES 12 E 323 VAL LYS SER SER LEU ALA GLN PRO LEU PHE ALA VAL ALA SEQRES 13 E 323 LEU LYS HIS GLN GLN PRO GLY VAL TYR ASP PHE GLY PHE SEQRES 14 E 323 ILE ASP SER SER LYS TYR THR GLY SER LEU THR TYR THR SEQRES 15 E 323 GLY VAL ASP ASN SER GLN GLY PHE TRP SER PHE ASN VAL SEQRES 16 E 323 ASP SER TYR THR ALA GLY SER GLN SER GLY ASP GLY PHE SEQRES 17 E 323 SER GLY ILE ALA ASP THR GLY THR THR LEU LEU LEU LEU SEQRES 18 E 323 ASP ASP SER VAL VAL SER GLN TYR TYR SER GLN VAL SER SEQRES 19 E 323 GLY ALA GLN GLN ASP SER ASN ALA GLY GLY TYR VAL PHE SEQRES 20 E 323 ASP CYS SER THR ASN LEU PRO ASP PHE SER VAL SER ILE SEQRES 21 E 323 SER GLY TYR THR ALA THR VAL PRO GLY SER LEU ILE ASN SEQRES 22 E 323 TYR GLY PRO SER GLY ASP GLY SER THR CYS LEU GLY GLY SEQRES 23 E 323 ILE GLN SER ASN SER GLY ILE GLY PHE SER ILE PHE GLY SEQRES 24 E 323 ASP ILE PHE LEU LYS SER GLN TYR VAL VAL PHE ASP SER SEQRES 25 E 323 ASP GLY PRO GLN LEU GLY PHE ALA PRO GLN ALA MODRES 1PPK SER E 3 SER GLYCOSYLATION SITE MODRES 1PPK THR E 7 THR GLYCOSYLATION SITE HET IVV E 700 35 HET MAN E 324 11 HET HSY E 325 9 HET SO4 E 326 5 HET DMF E 327 5 HETNAM IVV N-(3-METHYLBUTANOYL)-L-VALYL-N-{(1R)-1-[(R)-(2-ETHOXY- HETNAM 2 IVV 2-OXOETHYL)(HYDROXY)PHOSPHORYL]-3-METHYLBUTYL}-L- HETNAM 3 IVV VALINAMIDE HETNAM MAN ALPHA-D-MANNOPYRANOSE HETNAM HSY ALPHA-L-XYLOPYRANOSE HETNAM SO4 SULFATE ION HETNAM DMF DIMETHYLFORMAMIDE HETSYN IVV PHOSPHINIC ACID ANALOGUE OF STATIN (IVA)-VAL-VAL- HETSYN 2 IVV STA(P)-O-ET FORMUL 2 IVV C24 H46 N3 O7 P FORMUL 3 MAN C6 H12 O6 FORMUL 4 HSY C5 H10 O5 FORMUL 5 SO4 O4 S 2- FORMUL 6 DMF C3 H7 N O FORMUL 7 HOH *275(H2 O) HELIX 1 1 ALA E 12 GLU E 15 5 4 HELIX 2 2 PRO E 47 GLN E 51 5 5 HELIX 3 3 ASN E 58 GLY E 63 1 6 HELIX 4 4 SER E 109 ASP E 115 1 7 HELIX 5 5 PHE E 126 ASN E 130 5 5 HELIX 6 6 THR E 139 LYS E 145 1 7 HELIX 7 7 ASP E 171 LYS E 174 5 4 HELIX 8 8 ASP E 222 SER E 231 1 10 HELIX 9 9 PRO E 268 LEU E 271 5 4 HELIX 10 10 GLY E 299 LYS E 304 1 6 SHEET 1 A 7 TYR E 263 VAL E 267 0 SHEET 2 A 7 PHE E 256 ILE E 260 -1 O PHE E 256 N VAL E 267 SHEET 3 A 7 SER E 192 ALA E 200 -1 N ASP E 196 O SER E 259 SHEET 4 A 7 GLN E 203 ALA E 212 -1 O GLN E 203 N ALA E 200 SHEET 5 A 7 SER E 296 PHE E 298 1 N SER E 296 O SER E 209 SHEET 6 A 7 LEU E 219 LEU E 221 -1 N LEU E 220 O ILE E 297 SHEET 7 A 7 ILE E 287 SER E 289 1 N GLN E 288 O LEU E 219 SHEET 1 B 4 GLN E 237 ASP E 239 0 SHEET 2 B 4 GLY E 244 ASP E 248 -1 O GLY E 244 N ASP E 239 SHEET 3 B 4 THR E 282 GLY E 285 -1 N CYS E 283 O PHE E 247 SHEET 4 B 4 ASN E 273 PRO E 276 -1 N TYR E 274 O LEU E 284 SSBOND 1 CYS E 249 CYS E 283 1555 1555 2.08 LINK OG SER E 3 C1 MAN E 324 1555 1555 1.41 LINK OG1 THR E 7 C1 HSY E 325 1555 1555 1.40 CISPEP 1 GLN E 133 PRO E 134 0 7.22 CISPEP 2 GLY E 314 PRO E 315 0 -5.35 CRYST1 97.480 46.550 66.420 90.00 116.14 90.00 C 1 2 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.010259 0.000000 0.005034 0.00000 SCALE2 0.000000 0.021482 0.000000 0.00000 SCALE3 0.000000 0.000000 0.016771 0.00000